nanoliposomal C6-ceramide

Nanoliposomal C6-ceramide (CNL) is a nanoliposome-encapsulated formulation of the short-chain sphingolipid C6-ceramide (hexanoyl-D-erythro-sphingosine), developed by Keystone Nano Inc. with technology licensed from the Penn State Research Foundation. Natural ceramides are potent pro-apoptotic signaling molecules, but their therapeutic use is limited by extreme hydrophobicity and rapid metabolism. CNL overcomes these delivery challenges using an approximately 80-90 nanometer diameter nanoliposome bilayer. The drug exerts anti-tumor activity by inhibiting multiple survival pathways, including the glycolytic enzyme Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the PI3K/Akt and Protein Kinase C zeta (PKCζ) signaling axes. It also modulates integrin affinity to inhibit metastatic potential. CNL has been investigated in Phase I clinical trials for advanced solid tumors and has shown preclinical efficacy in models of hepatocellular carcinoma, chronic lymphocytic leukemia, and melanoma.

Other names

C6-ceramide nanoliposomeC-6-ceramide nanoliposomeC 6-ceramide nanoliposomehexanoyl-D-erythro-sphingosine nanoliposome